People: Prana Biotechnology Ltd (PRAN.PH)

PRAN.PH on Philadelphia Stock Exchange

2.37USD
20 May 2013
Price Change (% chg)

$0.12 (+5.33%)
Prev Close
$2.25
Open
$2.37
Day's High
$2.37
Day's Low
$2.37
Volume
100
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Summary

Name Age Since Current Position

Geoffrey Kempler

 57 2005 Executive Chairman of the Board, Chief Executive Officer

Richard Revelins

 2004 Chief Financial Officer, Company Secretary

Dianne Angus

 52 2007 Chief Operating Officer

Lawrence Gozlan

 33 2011 Non-Executive Independent Director

Peter Marks

 56 2005 Non-Executive Independent Director

Brian Meltzer

 58 1999 Non-Executive Independent Director

George Mihaly

 59 1999 Non-Executive Independent Director
» Insider Trading

Biographies

Name Description

Geoffrey Kempler

 Mr. Geoffrey Paul Kempler has served as Executive Chairman of the Board and Chief Executive Officer of Prana Biotechnology Ltd since June 16, 2005. Prior to that, he served as Chairman of the Board from August 2004. Between November 11, 1997 and August 2004 he served as the Chief Executive Officer, and Chairman of the Board of the Company. Mr. Kempler is one of the founders of the Company. He is a qualified psychologist and holds a Bachelor of Science degree in Science from Monash University and a Grad. Dip. App. Soc. Psych. degree from Swinburne University. At the Company, he has been responsible for the implementation of the strategic plan and the commercialisation of technology.

Richard Revelins

 Mr. Richard Revelins has served as Chief Financial Officer and Company Secretary of Prana Biotechnology Ltd since June 2004. He has served as the Company Secretary since February 2000. He serves as the company's Chief Financial Officer on a part-time basis and devotes approximately one to two work days a week to such position. Mr. Revelins is an executive director and principal of Peregrine Corporate Limited, an Australian-based investment bank, and Managing Director at Cappello Group Inc., a Santa Monica, Los Angeles based investment bank. Mr. Revelins has held senior positions in international merchant banks and is currently a director of Mining Project Group Limited, which is listed on the ASX as well as of a number of private companies. Mr. Revelins holds a Bachelor of Economics degree from Monash University, Melbourne.

Dianne Angus

 Ms. Dianne Angus has served as Chief Operating Officer of Prana Biotechnology Ltd since May 31, 2007. She joined the company on August 19, 2002, initially serving as Vice President of Intellectual Property and Licensing. She then was promoted to Senior Vice President of Business Development, Intellectual Property and Research in July 2004 and served in that position until being promoted to her current position in May 2007. From 1992 to 2000, Ms. Angus managed the intellectual property, licensing and biotechnology product development assets of two Australian companies, AMRAD Corporation Limited and Florigene Limited. At Florigene, Ms. Angus was the joint venture alliance manager with Suntory for three years. From June 2000 to August 2002, Ms. Angus was Director of Dianne Angus and Associates Pty. Ltd. providing strategic business development, technology evaluation and intellectual property consulting services to biotechnology companies. Ms. Angus has worked in the commercial biotechnology sector for over 18 years directing product valuation, acquisition and product licensing. During her career, Ms. Angus has managed diverse intellectual property portfolios, contract rights and enforcement. Ms. Angus has negotiated and executed many commercial licenses and research and product development agreements with entities ranging from pharmaceutical companies to numerous global research institutes. Ms. Angus has also undertaken due diligence assessments on several Australian biotechnology companies for investment brokers. Ms. Angus holds a Bachelor of Science (Education) and Bachelor of Science (Honours) degree from the University of Melbourne, a Master’s degree in Biotechnology from Monash University, a Graduate Diploma in Intellectual Property Law from Monash University, a Diploma in Intellectual Property Practice from the Institute of Patent and Trademark Attorneys of Australia and is a registered Australian Patent and Trade Mark Attorney.

Lawrence Gozlan

 Mr. Lawrence Gozlan has served as Non-Executive Independent Director of Prana Biotechnology Ltd since August 8, 2011. Mr. Gozlan, a biotechnology investor and advisor, is the Chief Investment Officer and Founder of Scientia Capital, a specialized global investment fund focused exclusively in life sciences. Scientia Capital was founded to provide high level experience and to manage investments for high net worth individuals, family offices and institutional investors seeking exposure to the biotechnology industry. Mr. Gozlan commenced his position with Scientia Capital in June 2006. Previously, Mr. Gozlan was responsible for the biotechnology investment portfolio in Australia as the institutional biotechnology analyst at the Queensland Investment Corporation (QIC), an investment fund with over AU$60 billion worth of assets under management. Mr. Gozlan also worked as the senior biotechnology analyst in the equities team at Foster Stock broking, and gained senior corporate finance experience advising life sciences companies at Deloitte. Mr. Gozlan is an investment advisor to several companies in the biotechnology industry, presented at numerous international healthcare conferences, and has been featured in various published media as an experienced person on investing in life sciences. He holds a Bachelor of Science with Honors in Microbiology and Immunology from the University of Melbourne, specializing in neurodegenerative diseases.

Peter Marks

 Mr. Peter Ashley Marks has served as Non-Executive Independent Director of Prana Biotechnology Ltd since July 29, 2005. For the period from November 21, 2006 to October 20, 2010, he also served as Executive Chairman of iSonea Ltd, formally KarmelSonix Ltd, a medical devices company listed on the ASX that is focused on developing and commercializing a range of devices in the respiratory and medicine space. Mr. Marks is currently also Director of Peregrine Corporate Limited, an Australian-based investment bank, and Watermark Global Plc, an AIM listed company, which commercializes the treatment and recycling of acid mine drainage water from South African mines. From September 1998 until March 2001, Mr. Marks was employed by KPMG Corporate Finance Ltd (Australia), where he rose to Director and was responsible for heading up the equity capital markets group in Melbourne. From January 1992 until July 1994, Mr. Marks served as Head of the Melbourne Companies Department at the ASX and was founding Director of Momentum Funds Management Pty Ltd, an Australian venture capital firm. From December 1990 until December 1991, Mr. Marks served as Director of Corporate Finance at Burdett Buckeridge & Young Ltd in their Melbourne offices, from August 1988 until November 1990, he held senior corporate finance position at Barings Securities Ltd, and from July 1985 until July 1988, he served as an Associate Director of Mclntosh Securities, now Merrill Lynch Australia. In his roles with these various financial institutions, Mr. Marks was responsible for advising a substantial number of listed and unlisted companies on issues ranging from corporate and company structure, to valuation, business strategies, acquisitions and international opportunities. Mr. Marks holds a Bachelor of Economics degree, a Bachelor of Law degree and Graduate Diploma in Commercial Law from Monash University in Melbourne, Australia, and an MBA degree from the Scottish School of Business at the University of Edinburgh.

Brian Meltzer

 Mr. Brian Derek Meltzer has served as Non-Executive Independent Director of Prana Biotechnology Ltd since December 9, 1999. He is also Chairman of the Company's Audit Committee, Remuneration Committee and Nomination Committee. He has over 30 years of experience in economics, finance and investment banking. Mr. Meltzer is a director of Momentum Ventures Limited, licensed by the government as an Innovation Investment Fund with venture capital investments including biotechnology, and Non-Executive Director on the Board of Directors of a number of private companies. He is also a Director on the board of the Australian-Israel Chamber of Commerce and is Deputy Chairman of Independence Australia (previously Paraquad). Mr. Meltzer holds a Bachelor of Commerce degree from the University of Auckland and a Master of Economics degree from Monash University.

George Mihaly

 Dr. George William Mihaly has served as Non-Executive Independent Director of Prana Biotechnology Ltd since December 9, 1999. Dr. Mihaly also serves as Director of Waide Pty Ltd., a private company. Dr. Mihaly has had a career spanning the research and commercial facets of the pharmaceutical industry. During the period from mid-1994 to early 2000, Dr. Mihaly was the founding executive Chairman and Managing Director of Synermedica Pty Ltd, or Synermedica, one of the Australia’s independent consultant research organizations to the pharmaceutical industry. Synermedica merged with the global consultant research organization Kendle International Inc. in April 2000 and Dr. Mihaly continued as Managing Director of the merged entity in Australia (now called Kendle Pty Ltd) until December 2004. Over the course of the last 35 years in academia and industry, Dr. Mihaly has amassed experience in both the science and logistics of setting up, monitoring, managing and evaluating results from Phase I, II, III and IV clinical trials. Dr. Mihaly holds a Bachelor of Pharmacy degree from Monash University, a Master of Science degree from Sydney University and a Ph.D. degree from Melbourne University, and he is a fellow of the Australian Institute of Company Directors.

Basic Compensation

Name Fiscal Year Total

Geoffrey Kempler

 416,579

Richard Revelins

 81,681

Dianne Angus

 374,850

Lawrence Gozlan

 36,667

Peter Marks

 55,000

Brian Meltzer

 90,000

George Mihaly

 75,000
As Of 29 Jun 2012

Options Compensation

Name Options Value

Geoffrey Kempler

 0 0

Richard Revelins

 0 0

Dianne Angus

 0 0

Lawrence Gozlan

 0 0

Peter Marks

 0 0

Brian Meltzer

 0 0

George Mihaly

 0 0

Insider Trading

» Full list on Insider Trading
Search Stocks